HER2 Gene Mutation Completed Phase 2 Trials for Poziotinib (DB12114)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02979821Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)Treatment